US-based biotechnology company Arnatar Therapeutics has successfully closed a $50 million Series A financing round, marking a significant step in the firm’s expansion plans into the Chinese market. The funding round, co-led by 3E Bioventures and Eight Roads, attracted substantial Chinese investment, highlighting the growing interest in innovative biotech solutions from both domestic and international investors.
Participating in the round were a consortium of prominent venture capital firms, including Legend Starr, the venture capital arm of Transfar Group, Huajin Capital, Gaorong Capital, Jifeng Ventures, New Alliance Capital, and Yijing Capital. This influx of capital will be instrumental in bolstering Arnatar’s research and development efforts and establishing a strong foothold in the lucrative China market.
Founded in San Diego in 2022 by Dr. Liang Xuehai, an industry veteran with expertise in antisense therapeutics and a former executive at Ionis Pharmaceuticals (Nasdaq: IONS), Arnatar Therapeutics specializes in the development of small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs). These cutting-edge technologies are designed to modulate gene expression within cells, offering potential treatments for a broad spectrum of diseases, including both common and rare conditions. The company is currently concentrating its efforts on therapies targeting liver and extrahepatic organs.
This Series A round follows an earlier seed round, in which Arnatar raised 100 million RMB (approximately $13.8 million), with participation from China-based Apricot Capital. The successful fundraising activities underscore the company’s rapid growth and the strong financial backing it has garnered since its inception.- Flcube.com
